RNA Q3 2021 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+23.9% YoY

Gross Profit

-$23M-1048.0% margin

Operating Income

-$29M-1353.7% margin

Net Income

-$29M-1353.4% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

-17.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$426M

Total Liabilities

$31M

Stockholders' Equity

$395M

Cash & Equivalents

$410M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+23.9%
Gross Profit	-$23M	-$8M	-194.0%
Operating Income	-$29M	-$11M	-155.4%
Net Income	-$29M	-$11M	-155.9%